Arthrolense Appoints Oren Gelman as CEO to Drive Innovation in Machine Vision for Surgical Guidance
Arthrolense, a Toronto-based leader in visual surgical guidance technology for joint replacement, has appointed Oren Gelman as President and CEO. The appointment marks a significant step in the company’s mission to transform orthopedic surgery by integrating machine vision with machine learning to provide real-time insights. Co-founders Dr. David Backstein and Dr. Russ Nevins will continue to guide the company’s clinical and strategic direction as Gelman leads the company into its next phase.
Gelman brings over 20 years of leadership experience in the medical device sector, with a proven track record of scaling global businesses and driving the adoption of advanced surgical technologies. Previously, Gelman held leadership positions at DePuy Synthes, Ethicon, and Stryker Orthopaedics, where he led large platforms, spearheaded major product launches, and expanded portfolios. His expertise in driving innovation in surgical technologies positions him well to lead Arthrolense in advancing its flagship 4DI visual guidance system.
Arthrolense’s 4DI system integrates patented camera technology and machine vision to provide surgeons with accurate, real-time anatomical visualization during joint replacement procedures. The system enables dynamic assessment of joint anatomy at the point of care, offering surgeons crucial intraoperative mapping and tracking. By enhancing surgical decision-making and reducing variability, the system aims to improve surgical outcomes and support personalized care for patients.
In his new role, Gelman expressed his enthusiasm for leading the company through a pivotal phase in its growth. “Arthrolense is addressing significant unmet needs in orthopedics—equipping surgeons with accurate, real-time insights through machine vision and machine learning that are designed to enhance decision-making, increase personalization, and improve both surgeon and patient satisfaction,” said Gelman. “I am honored to work with the talented team and visionary co-founders at Arthrolense to advance the technology toward commercialization and bring it to market for the benefit of patients and surgeons alike.”
In addition to its technological advancements, Arthrolense is making strides in its regulatory and commercial preparations. The company has established a quality management system that meets global regulatory standards and is actively preparing for FDA submission. Arthrolense is also expanding its patent portfolio and exploring strategic partnerships to support its global market entry and scalability.
The company’s focus on intelligent, machine vision-enabled surgery aims to set a new standard in orthopedic care, addressing high-priority clinical needs and advancing the field of joint replacement surgery.
